NEURAXIS INC (NRXS) Stock Price, Quote, News and Overview
NYSEARCA:NRXS - NYSE Arca - US64134X2018 - Common Stock - Currency: USD
NRXS Quote, Performance and Key Statistics
3.99
+1.72 (+75.77%)
The current stock price of NRXS is 3.99 USD. In the past month the price increased by 104.62%. In the past year, price increased by 26.27%.
NRXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.28 | 234.48B | ||
| ISRG | INTUITIVE SURGICAL INC | 72.93 | 199.70B | ||
| BSX | BOSTON SCIENTIFIC CORP | 39.46 | 157.58B | ||
| SYK | STRYKER CORP | 31.09 | 148.69B | ||
| MDT | MEDTRONIC PLC | 16.17 | 110.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.54 | 50.73B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.93 | 45.76B | ||
| IDXX | IDEXX LABORATORIES INC | 45.36 | 41.91B | ||
| RMD | RESMED INC | 27.33 | 36.38B | ||
| DXCM | DEXCOM INC | 52.93 | 34.25B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.62 | 32.90B | ||
| STE | STERIS PLC | 26.82 | 24.61B |
Related stock screener links
About NRXS
Company Profile
NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 21 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Company Info
NEURAXIS INC
11611 N. Meridian St, Suite 330
Carmel INDIANA US
Employees: 21
Phone: 18126890791
NEURAXIS INC / NRXS FAQ
What is the stock price of NEURAXIS INC today?
The current stock price of NRXS is 3.99 USD. The price increased by 75.77% in the last trading session.
What is the ticker symbol for NEURAXIS INC stock?
The exchange symbol of NEURAXIS INC is NRXS and it is listed on the NYSE Arca exchange.
On which exchange is NRXS stock listed?
NRXS stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for NEURAXIS INC stock?
7 analysts have analysed NRXS and the average price target is 4.85 USD. This implies a price increase of 21.43% is expected in the next year compared to the current price of 3.99. Check the NEURAXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEURAXIS INC worth?
NEURAXIS INC (NRXS) has a market capitalization of 28.81M USD. This makes NRXS a Nano Cap stock.
How many employees does NEURAXIS INC have?
NEURAXIS INC (NRXS) currently has 21 employees.
What are the support and resistance levels for NEURAXIS INC (NRXS) stock?
NEURAXIS INC (NRXS) has a support level at 2.19. Check the full technical report for a detailed analysis of NRXS support and resistance levels.
Is NEURAXIS INC (NRXS) expected to grow?
The Revenue of NEURAXIS INC (NRXS) is expected to grow by 31306.7% in the next year. Check the estimates tab for more information on the NRXS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEURAXIS INC (NRXS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NRXS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NRXS, evaluating the profitability, health, valuation and growth aspects
- NEURAXIS INC (NRXS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEURAXIS INC (NRXS) Sales and EPS estimates to see what analysts future expectations are.
- NEURAXIS INC (NRXS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEURAXIS INC (NRXS) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEURAXIS INC (NRXS) Stock Chart to make your own analysis
- NEURAXIS INC (NRXS) Latest news and press-releases to stay up to date.
Does NEURAXIS INC (NRXS) stock pay dividends?
NRXS does not pay a dividend.
What is the Price/Earnings (PE) ratio of NEURAXIS INC (NRXS)?
NEURAXIS INC (NRXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.22).
What is the Short Interest ratio of NEURAXIS INC (NRXS) stock?
The outstanding short interest for NEURAXIS INC (NRXS) is 0.3% of its float. Check the ownership tab for more information on the NRXS short interest.
NRXS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NRXS. When comparing the yearly performance of all stocks, NRXS is one of the better performing stocks in the market, outperforming 95.7% of all stocks.
NRXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NRXS. While NRXS seems to be doing ok healthwise, there are quite some concerns on its profitability.
NRXS Financial Highlights
Over the last trailing twelve months NRXS reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS increased by 94.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -177.67% | ||
| ROE | -408.78% | ||
| Debt/Equity | 0 |
NRXS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NRXS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -880% and a revenue growth 31306.7% for NRXS